NEW HAVEN, Conn.--()--Ikonisys announced today that they will exhibit their proprietary oncoFISH® cervical test at the Eurogin 2010 Cervical Cancer Prevention Conference held at the Grimaldi Forum in Monte Carlo from February 17-20.
oncoFISH cervical is a companion test designed to work in conjunction with currently used cervical cancer screening tests like the Pap smear and HPV tests prior to colposcopy. oncoFISH cervical serves as an additional aid for medical professionals to better manage cervical dysplasia.
Currently offered in the United States as a laboratory developed test, Ikonisys will now launch this test to the broader European market as a CE marked product. Centro Diagnostico Italiano (CDI), a full service outpatient health facility, was the first in Europe to offer oncoFISH cervical out of their laboratory. “The objective presence of cells with a significant amplification of 3q26 is the smoking gun in the pathogenesis of cervical cancer: finally we can give our gynecologists a clearer picture. The oncoFISH cervical test enables us to offer a new dimension of cervical cancer diagnosis and we are thrilled to be the first in Europe to offer such a test,” said Vittorio Grazioli, MD. Located in Milan, CDI averages over 3.7 million diagnostic tests per year.
Based on enumerating fluorescence markers in the 3q region, the oncoFISH cervical test will be sold as an application for the Ikoniscope® Digital Microscopy System. The Ikoniscope and oncoFISH cervical probe kits will be sold directly to customers throughout Europe.
In addition to the conference, Ikonisys will be holding a workshop to further demonstrate and explain the clinical value of this test. For more information on Ikonisys’ oncoFISH cervical test, please visit www.ikonisys.com/cervical.
About Ikonisys
Founded in 1999, Ikonisys, Inc. is a privately-held, next generation diagnostic company specializing in non-invasive, cell-based diagnostics. Ikonisys has developed the CellOptics® platform, a robotic microscopy technology for fully-automated, high-throughput identification and analysis of rare cells by fluorescence in-situ hybridization (FISH).
A pipeline of applications is being developed for cancer diagnosis and management (oncoFISH®) and a non-invasive prenatal screening test for Down syndrome (fastFISH® fetal) to be run on the Ikoniscope® using the CellOptics technology. Additionally, Ikonisys has developed a novel approach for the enrichment, identification and characterization of circulating tumor cells (CTC).
Ikonisys’ first proprietary test, oncoFISH® cervical, is offered as a Laboratory Developed Test through the Company’s CAP-accredited clinical laboratory. In addition to oncoFISH cervical, the Company offers three FDA-cleared applications that automate certain commercially available FISH tests.
To learn more visit www.ikonisys.com.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
